Kyverna to Host April 22 Call on KYSA-8 and KYSA-6 Trial Data
Kyverna will host an April 22 conference call to discuss primary analysis from its KYSA-8 registrational trial in stiff person syndrome and long-term follow-up from the KYSA-6 Phase 2 study in generalized myasthenia gravis. Both datasets will be presented orally at AAN in Chicago April 20-21.
1. Conference Call and Webcast
Kyverna has scheduled a conference call for April 22 at 7:00 a.m. ET to review primary analysis from KYSA-8 and follow-up data from KYSA-6. Participants must register online to receive dial-in details and can access a live webcast and on-demand replay via the Events & Presentations section of the Investor Relations website.
2. KYSA-8 Registrational Trial Primary Analysis
The KYSA-8 registrational trial of mivocabtagene autoleucel (KYV-101) in stiff person syndrome will report primary efficacy and safety outcomes as part of its pivotal Phase 2 study. These results will inform potential regulatory submission pathways by demonstrating treatment impact on muscle stiffness and spasm frequency.
3. KYSA-6 Phase 2 Long-Term Follow-Up
The KYSA-6 open-label Phase 2 trial in generalized myasthenia gravis will present extended remission durability and safety follow-up data. Results will detail antibody titers, functional scores and relapse rates beyond initial treatment, offering insights into long-term disease control.
4. AAN Presentation Schedule
Oral presentations will take place in Chicago on April 20 at 1:48 p.m. CT for KYSA-6 follow-up data and April 21 at 6:27 p.m. CT for KYSA-8 primary analysis. Two poster sessions on real-world outcomes and Phase 3 study design will also be held on April 20 and 21.